NCT04563975 is a Phase 2 clinical trial of Toripalimab in Gastric Cancer Stage IV, sponsored by Tao Zhang.

Who is sponsoring NCT04563975?

NCT04563975 is sponsored by Tao Zhang.

What drugs are being tested in NCT04563975?

Interventions in NCT04563975: Toripalimab, Docetaxel, nab-paclitaxel.

What condition does NCT04563975 study?

NCT04563975 studies Gastric Cancer Stage IV.

Is NCT04563975 still recruiting?

NCT04563975 is currently status unknown. Last updated 17 March 2021.

Last reviewed 2021-03-17 · How we verify

NCT04563975

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer

Status unknown Phase 2 Last updated 17 March 2021

What this trial tests

Phase 2 trial testing Toripalimab in Gastric Cancer Stage IV in 54 participants. Status unknown.

Timeline

2 July 2020

Primary endpoint
31 December 2022

30 May 2023

Quick facts

Lead sponsor	Tao Zhang
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	54
Start date	2 July 2020
Primary completion	31 December 2022
Estimated completion	30 May 2023
Sites	1 location across China

Drugs / interventions tested

Toripalimab (TORIPALIMAB) — full drug profile →
Docetaxel (Docetaxel) — full drug profile →
nab-paclitaxel (nab-paclitaxel) — full drug profile →

Conditions studied

Gastric Cancer Stage IV — all drugs for Gastric Cancer Stage IV →

Sponsor

Tao Zhang — full company profile →

Who can join

Adults 18 to 75, any sex, with Gastric Cancer Stage IV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The single arm clinical study is to evaluate the efficacy and safety of an anti-PD-1 antibody (Toripalimab) combined with chemotherapy (docetaxel or nab-Paclitaxel) in patients with advanced gastric cancer who failed first-line treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Toripalimab

Trials testing the same drug.

NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07423078 — Window of Opportunity in Preserving Laryngeal Function Trial · Phase 2 · recruiting
NCT07480733 — Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors · Phase 2 · not yet recruiting
NCT07320963 — Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. · Phase 1, PHASE2 · not yet recruiting
NCT07469956 — Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancre · Phase 2 · not yet recruiting

Other recruiting trials for Gastric Cancer Stage IV

Currently open trials in the same condition.

NCT05319639 — Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab · Phase 1, PHASE2 · recruiting
NCT04592211 — Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer · Phase 1, PHASE2 · recruiting

Other Tao Zhang trials

Trials by the same sponsor.

NCT07113275 — A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Ne · Phase 3 · not yet recruiting
NCT07353268 — Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/ · Phase 2 · not yet recruiting
NCT07243938 — Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET) · Phase 2 · not yet recruiting
NCT07239466 — A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunoth · Phase 2 · not yet recruiting
NCT07000305 — A Study of Cetuximabβ Combined With Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04563975 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tao Zhang
Last refreshed: 17 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04563975.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing